In ACC, several potential immunotherapeutic targets have been identified in preclinical studies, including B7H3, ROR1, and an antigen that yet to be disclosed.103, -105 B7H3 may be of particular interest as a promising target, as B7H3 CAR-T cells have shown activity in children and young adults with solid tumors.106 A phase I trial of autologous B7H3 CAR-T cells in children with advanced solid tumors, including ACC, is underway (Table 2).107. This evidence concerns the gene CD276 and adrenal cortex carcinoma.